



# FINANCIAL DATA

**Fiscal Year Ending March 31, 2016**

**[2016年3月期 第3四半期]**

April 1, 2015 – December 31, 2015

目次	CONTENTS	
<連結データ> < Consolidated Data >		
連結決算概要	Financial Summary (Consolidated)	1
連結貸借対照表	Consolidated Balance Sheets	3
連結損益計算書	Consolidated Income Statement	5
連結キャッシュフロー計算書	Consolidated Cash Flow Statement	6
地域別・事業別・品目別売上高	Net Sales by Destination, Business and Product type	8
地域別・事業別売上高	Net Sales by Destination and Business	9
地域別・品目別売上高	Net Sales by Destination and Product type	12
所在地別売上高および営業利益の状況	Net Sales and Operating Income (Loss) by Geographical Region (Net Sales and Operating Income (Loss) of Subsidiaries in the Region)	13
<関連データ> < Associated Data >		
株式情報	Stock Information	14
会社概要	Corporate Data	15

- 2014年4月1日付で1株を2株に株式分割を実施しました。
- The shares of shareholders was split two for one on April 1, 2014.
- 2014年3月期第3四半期にアイノスティクス ゲーエムベーパー及びその関係会社を子会社化しました。
- In the 3rd quarter of the fiscal year ending March 31, 2014, Inostics GmbH and its affiliated companies were converted to subsidiaries.
- 2014年3月期第2四半期にバルテック ゲーエムベーパー ゲルリッツ及びその関係会社の持分を取得し、子会社化しました。
- In the 2nd quarter of the fiscal year ending March 31, 2014, Sysmex acquired Partec GmbH Görlitz and its ownership in affiliated companies and converted these companies to subsidiaries.
- 2014年3月期第1四半期の連結決算より、シスメックスビジネスサポート株式会社、シスメックスコリアの業績が反映されています。
- At the beginning of 1st quarter of fiscal year ending March 31, 2014, the consolidated figures include the results of Sysmex Business Support Co., Ltd. and Sysmex Korea Co., Ltd.
- 2011年4月1日付で1株を2株に株式分割を実施しました。
- The shares of shareholders was split two for one on April 1, 2011.

本資料のうち、業績見通し等に記載されている各数値は、現在入手可能な情報による判断および仮定に基づき算出しており、判断や仮定に内在する不確実性および今後の事業運営や内外の状況変化により、実際の業績等が見通しの数値と大きく異なる可能性があります。

#### Forward-looking Statements

This material contains forward-looking statements about Sysmex Corporation and its group companies (the Sysmex Group). These forward-looking statements are based on current judgments and assumptions of the Sysmex Group in light of the information currently available to it, and involve known and unknown risks, uncertainties and other factors, including but not limited to: global economic conditions, competitive situations and changes in exchange rates. Such risks, uncertainties and other factors may cause our actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by these forward-looking statements.

# 連結データ

## Consolidated Data

### 連結決算概要 [第3四半期累計]

#### Financial Summary(Consolidated) [3rd Quarter]

(百万円) (構成比:%)  
(¥ million) (Ratio: %)

項目 Item	決算期 Fiscal Term	2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q	2016.3 通期予想 (Forecast)
売上高	Net Sales (百万円) (¥ million)	96,913	101,383	129,849	155,852	185,685	252,000
売上総利益	Gross Profit (百万円) (¥ million)	61,130	63,848	※1 81,860	90,843	111,635	147,000
営業利益	Operating Income (百万円) (¥ million)	13,654	15,192	22,123	31,517	42,207	52,000
経常利益	Ordinary Income (百万円) (¥ million)	13,226	15,568	23,159	33,137	41,071	51,400
親会社株主に帰属する四半期(当期)純利益 ※2	Profit Attributable to Owners of Parent (百万円) (¥ million)	8,584	9,518	14,002	20,620	27,085	33,000
1株当たり四半期(当期)純利益	Profit per Share (円) (¥)	83.55	92.49	135.46	99.48	130.41	159.07
自己資本四半期(当期)純利益率	Return on Equity [ROE] (%)	-	-	-	-	-	-
売上総利益率	Gross Profit per Net Sales (%)	63.1	63.0	※1 63.7	58.3	60.1	58.3
売上高営業利益率	Operating Income to Net Sales (%)	14.1	15.0	17.0	20.2	22.7	20.6
売上高経常利益率	Ordinary Income to Net Sales (%)	13.6	15.4	17.8	21.3	22.1	20.4
売上高四半期(当期)純利益率	Profit Attributable to Owners of Parent to Net Sales (%)	8.9	9.4	10.8	13.2	14.6	13.1

項目 Item	決算期 Fiscal Term	2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q	増減 (Variance)
資本金	Capital Stock (百万円) (¥ million)	9,136	9,471	10,138	10,405	10,912	507
自己株控除後期末株式数	Number of Shares Outstanding (千株) (thousand shares)	102,773.5	103,010.9	103,482.3	207,340.5	207,835.8	495.3
純資産	Net Assets (百万円) (¥ million)	96,099	110,971	139,076	166,028	183,921	17,893
総資産	Total Assets (百万円) (¥ million)	130,945	152,869	198,635	234,607	255,228	20,621
自己資本比率	Equity Ratio (%)	72.9	72.2	69.8	70.4	71.6	1.2
1株当たり純資産	Net Assets per Share (円) (¥)	928.58	1,071.61	1,340.29	796.46	879.42	82.96

項目 Item	決算期 Fiscal Term	2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q
営業活動によるキャッシュ・フロー	Net Cash Provided by (Used in) Operating Activities (百万円) (¥ million)	9,955	16,664	22,270	24,111	23,905
投資活動によるキャッシュ・フロー	Net Cash Provided by (Used in) Investment Activities (百万円) (¥ million)	△ 7,754	△ 9,445	△ 28,768	△ 14,963	△ 15,181
財務活動によるキャッシュ・フロー	Net Cash Provided by (Used in) Financing Activities (百万円) (¥ million)	△ 2,701	△ 3,464	81	△ 7,677	△ 8,908
現金及び現金同等物の期末残高	Cash and Cash Equivalents at End of Term (百万円) (¥ million)	17,791	26,435	30,711	41,511	48,592

※1 2015.3.1Qより、販売した製商品を顧客へ届けるための運送費を売上原価に計上する方法にグループ内で統一しました。なお、2014.3期については遡及適用後の財務諸表となっております。

※During the first quarter of the fiscal year ending March 31, 2015, Sysmex has adopted consistently throughout the Group the practice of including transportation costs for shipping sold products to customers within cost of sales.

The financial statements for the fiscal year ended March 31, 2014, have been retroactively adjusted.

※2 2015年3月期以前の数値は「四半期(当期)純利益」の数値です。

※2 Figures shown for fiscal years ended on or before March 31, 2015 are "Net income."

●2014年4月1日付で1株を2株に株式分割を行っております。そのため、前連結会計年度の期首に当該分割が行われたと仮定して期末発行済株式数を算定しております。

●The Company conducted a two-for-one stock split on April 1, 2014. Accordingly, calculations involving the number of shares issued as of the end of the fiscal year are performed as if the stock split had been conducted at the beginning of the previous fiscal year.

●2015.3.1Q以降、サービスコスト等の表示区分を変更しております。

●The presentation of service cost and other categories has been revised from the first three months of the fiscal year ended March 31, 2015.

●通期予想は、2015年11月に修正したものです。

●Business forecast was revised in November 2015.

換算レート（通期実績）  
Average Exchange Rates (Annual)

				決算期 Fiscal Term		2012.3 F.Y.	2013.3 F.Y.	2014.3 F.Y.	2015.3 F.Y.	2016.3 通期予想 (Forecast)
USDドル	USD	(円)	(¥)			79.1	83.1	100.2	109.9	118.4
ユーロ	EUR	(円)	(¥)			109.0	107.2	134.4	138.8	132.5
元	CNY	(円)	(¥)			12.4	13.2	16.3	17.8	19.0

換算レート（期中平均）  
Average Exchange Rates (Periods)

				決算期 Fiscal Term		2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q
USDドル	USD	(円)	(¥)			79.0	80.0	99.4	106.9	121.7
ユーロ	EUR	(円)	(¥)			110.6	102.2	132.2	140.3	134.4
元	CNY	(円)	(¥)			12.3	12.7	16.1	17.4	19.3

設備投資の状況  
Capital Expenditure

				決算期 Fiscal Term		2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q	2016.3 通期予想 (Forecast)
設備投資	Capital Expenditure	(百万円)	(¥ million)			4,517	6,796	8,328	9,363	9,243	16,000
減価償却費	Depreciation and Amortization	(百万円)	(¥ million)			5,260	5,775	7,178	8,357	9,133	12,400
研究開発費	R&D Expenditure	(百万円)	(¥ million)			8,874	8,872	9,728	10,490	12,579	16,200
研究開発費対売上比率	R&D Expenditure per Net Sales	(%)				9.2	8.8	7.5	6.7	6.8	6.6

●通期予想は、2015年11月に修正したものです。

●Business forecast was revised in November 2015.

Consolidated Balance Sheets

資産の部  
Assets Section

(百万円) (構成比: %)  
(¥ million) (Ratio: %)

項目 Item	2012.3 F.Y.		2013.3 F.Y.		2014.3 F.Y.		2015.3 F.Y.		2016.3 3Q		増減 (Variance)
		%		%		%		%		%	
<b>流動資産</b> Current Assets	90,160	63.4	114,411	66.1	125,823	59.7	154,148	62.2	159,533	62.5	5,385
現金及び預金	21,362	15.0	33,830	19.6	36,698	17.4	50,272	20.3	48,639	19.1	△1,633
受取手形及び売掛金 Notes and Accounts Receivable-trade	36,218	25.5	41,254	23.8	45,514	21.6	53,038	21.4	50,545	19.8	△2,493
リース投資資産 Lease Investment Assets	2,576	1.8	3,262	1.9	4,640	2.2	5,413	2.2	6,682	2.6	1,269
有価証券 Marketable Securities	745	0.5	627	0.4	131	0.1	240	0.1	235	0.1	△5
たな卸資産 Inventories	21,843	15.4	25,940	15.0	27,319	13.0	29,888	12.1	37,861	14.8	7,973
繰延税金資産 Deferred Tax Assets	5,129	3.6	6,029	3.5	8,011	3.8	8,987	3.6	7,756	3.0	△1,231
前払費用 Prepaid Expenses	1,330	0.9	1,342	0.8	1,600	0.8	1,991	0.8	2,113	0.8	122
短期貸付金 Short-term Loans Receivable	1	0.0	43	0.0	1	0.0	1	0.0	-	-	△1
その他 Others	1,302	0.9	2,603	1.5	2,793	1.3	4,890	2.0	6,290	2.5	1,400
貸倒引当金 Allowance for Doubtful Accounts	△350	△0.2	△523	△0.3	△889	△0.4	△575	△0.2	△591	△0.2	△16
<b>固定資産</b> Noncurrent Assets	52,124	36.6	58,599	33.9	84,935	40.3	93,835	37.8	95,694	37.5	1,859
<b>有形固定資産</b> Property, Plant and Equipment	39,839	28.0	45,478	26.3	53,774	25.5	59,061	23.8	60,706	23.8	1,645
建物及び構築物 Buildings and Structures	16,736	11.8	18,652	10.8	18,855	8.9	22,425	9.0	24,738	9.7	2,313
機械装置及び運搬具 Machinery, Equipment and Vehicles, Net	2,609	1.8	3,102	1.8	3,235	1.5	3,895	1.6	4,232	1.7	337
工具、器具及び備品 Tools, Furniture and Fixtures, Net	9,857	6.9	12,353	7.1	15,145	7.2	16,834	6.8	17,428	6.8	594
土地 Land	8,893	6.3	10,023	5.8	11,264	5.3	11,259	4.5	11,311	4.4	52
リース資産 Lease Assets, Net	618	0.4	525	0.3	595	0.3	510	0.2	492	0.2	△18
建設仮勘定 Construction in Progress	1,124	0.8	821	0.5	4,678	2.2	4,136	1.7	2,503	1.0	△1,633
<b>無形固定資産</b> Intangible Assets	6,903	4.9	6,885	4.0	23,858	11.3	23,783	9.6	22,845	9.0	△938
のれん Goodwill	2,194	1.5	1,790	1.0	13,115	6.2	12,114	4.9	9,772	3.8	△2,342
ソフトウェア Software	4,447	3.1	4,654	2.7	5,969	2.8	7,112	2.9	8,801	3.4	1,689
その他 Others	262	0.2	440	0.3	4,773	2.3	4,555	1.8	4,270	1.7	△285
<b>投資その他の資産</b> Investments and Other Assets	5,381	3.8	6,234	3.6	7,303	3.5	10,990	4.4	12,143	4.8	1,153
投資有価証券 Investment Securities	3,259	2.3	4,035	2.3	4,672	2.2	7,174	2.9	7,598	3.0	424
長期貸付金 Long-term Loans Receivable	14	0.0	14	0.0	13	0.0	11	0.0	37	0.0	26
繰延税金資産 Deferred Tax Assets	87	0.1	125	0.1	132	0.1	267	0.1	303	0.1	36
退職給付に係る資産 Net defined benefit assets	-	-	-	-	-	-	960	0.4	1,553	0.6	593
長期前払費用 Long-term Prepaid Expenses	318	0.2	323	0.2	353	0.2	419	0.2	443	0.2	24
その他 Others	1,704	1.2	1,739	1.0	2,134	1.0	2,161	0.9	2,209	0.9	48
貸倒引当金 Allowance for Doubtful Accounts	△3	△0.0	△3	△0.0	△3	△0.0	△3	△0.0	△3	△0.0	-
<b>資産合計</b> Total Assets	142,285	100.0	173,010	100.0	210,758	100.0	247,983	100.0	255,228	100.0	7,245

負債・純資産の部  
Liabilities and Net Assets

(百万円) (構成比:%)  
(¥ million) (Ratio: %)

項目 Item	決算期 Fiscal Term	2012.3 F.Y.		2013.3 F.Y.		2014.3 F.Y.		2015.3 F.Y.		2016.3 3Q		増減 (Variance)
			%		%		%		%		%	
<b>流動負債</b>	<b>Current Liabilities</b>	34,728	24.4	45,424	26.3	54,010	25.6	65,170	26.3	57,454	22.5	△7,716
支払手形及び買掛金	Notes and Accounts Payable-trade	12,176	8.6	14,832	8.6	13,263	6.3	15,965	6.4	20,639	8.1	4,674
短期借入金	Short-term Loans Payable	5	0.0	3	0.0	1,050	0.5	-	-	0	0.0	0
リース債務	Current Portion of Lease Obligations	252	0.2	53	0.0	57	0.0	50	0.0	39	0.0	△11
未払費用	Accrued Expenses	4,417	3.1	5,598	3.2	7,115	3.4	8,301	3.3	7,580	3.0	△721
未払法人税等	Income Taxes Payable	2,776	2.0	3,982	2.3	7,699	3.7	9,639	3.9	5,023	2.0	△4,616
繰延税金負債	Deferred Tax Liabilities	-	-	6	0.0	8	0.0	101	0.0	259	0.1	158
賞与引当金	Provision for Bonuses	3,622	2.5	4,043	2.3	5,047	2.4	6,119	2.5	4,314	1.7	△1,805
役員賞与引当金	Provision for Directors' Bonuses	248	0.2	265	0.2	269	0.1	411	0.2	387	0.2	△24
製品保証引当金	Provision for Product Warranties	157	0.1	175	0.1	291	0.1	456	0.2	490	0.2	34
その他	Others	11,070	7.8	16,462	9.5	19,205	9.1	24,124	9.7	18,719	7.3	△5,405
<b>固定負債</b>	<b>Noncurrent Liabilities</b>	5,053	3.6	8,432	4.9	10,498	5.0	13,262	5.3	13,852	5.4	590
長期借入金	Long-term Loans Payable	4	0.0	1	0.0	105	0.0	-	-	1	0.0	1
リース債務	Lease Obligations	257	0.2	245	0.1	251	0.1	199	0.1	182	0.1	△17
繰延税金負債	Deferred Tax Liabilities	1,759	1.2	3,074	1.8	6,078	2.9	8,993	3.6	9,464	3.7	471
退職給付引当金	Provision for Retirement Benefits	1,263	0.9	1,747	1.0	-	-	-	-	-	-	-
役員退職慰労引当金	Provision for Directors' Retirement Benefits	160	0.1	160	0.1	102	0.0	102	0.0	102	0.0	-
退職給付に係る負債	Net defined benefit liability	-	-	-	-	631	0.3	460	0.2	478	0.2	18
その他	Others	1,607	1.1	3,203	1.9	3,329	1.6	3,507	1.4	3,621	1.4	114
<b>負債合計</b>	<b>Total Liabilities</b>	39,782	28.0	53,857	31.1	64,508	30.6	78,432	31.6	71,306	27.9	△7,126
<b>株主資本</b>	<b>Shareholders' Equity</b>	106,543	74.9	118,050	68.2	135,133	64.1	155,330	62.6	172,894	67.7	17,564
資本金	Capital Stock	9,187	6.5	9,711	5.6	10,243	4.9	10,483	4.2	10,912	4.3	429
資本剰余金	Capital Surplus	14,127	9.9	14,651	8.5	15,183	7.2	15,423	6.2	15,852	6.2	429
利益剰余金	Retained Earnings	83,484	58.7	93,947	54.3	109,976	52.2	129,703	52.3	146,414	57.4	16,711
自己株式	Treasury Stock	△255	△0.2	△259	△0.2	△270	△0.1	△280	△0.1	△285	△0.1	△5
その他の包括利益累計額	Other Comprehensive Income	△4,709	△3.3	749	0.4	10,623	5.0	13,196	5.3	9,881	3.9	△3,315
その他有価証券評価差額金	Valuation Difference on Available-for-sale Securities	426	0.3	708	0.4	1,134	0.5	1,366	0.6	1,446	0.6	80
繰延ヘッジ損益	Deferred Gains or Losses on Hedges	-	-	-	-	-	-	-	-	25	0.0	25
為替換算調整勘定	Foreign Currency Translation Adjustments	△5,136	△3.6	41	0.0	8,652	4.1	10,428	4.2	7,536	3.0	△2,892
退職給付に係る調整累計額	Remeasurements of defined benefit plans	-	-	-	-	836	0.4	1,400	0.6	872	0.3	△528
新株予約権	Subscription Rights to Shares	546	0.4	353	0.2	493	0.2	1,024	0.4	1,145	0.4	121
非支配株主持分	Non-controlling interests	122	0.1	-	-	-	-	-	-	0	0.0	0
<b>純資産合計</b>	<b>Total Net Assets</b>	102,502	72.0	119,153	68.9	146,250	69.4	169,550	68.4	183,921	72.1	14,371
<b>負債・純資産合計</b>	<b>Total Liabilities and Net Assets</b>	142,285	100.0	173,010	100.0	210,758	100.0	247,983	100.0	255,228	100.0	7,245

Consolidated Income Statement [3rd Quarter]

(百万円) (構成比:%)  
(\* million) (Ratio:%)

項目 Item	決算期 Fiscal Term	2012.3 3Q		2013.3 3Q		2014.3 3Q		2015.3 3Q		2016.3 3Q	
			%		%		%		%		%
売上高	Net Sales	96,913	100.0	101,383	100.0	129,849	100.0	155,852	100.0	185,685	100.0
売上原価	Cost of Sales	35,782	36.9	37,534	37.0	※1 47,988	37.0	65,009	41.7	74,049	39.9
売上総利益	Gross Profit	61,130	63.1	63,848	63.0	※1 81,860	63.0	90,843	58.3	111,635	60.1
販売費及び一般管理費	Selling, General and Administrative	47,475	49.0	48,656	48.0	※1 59,736	46.0	59,326	38.1	69,428	37.4
営業利益	Operating Income	13,654	14.1	15,192	15.0	22,123	17.0	31,517	20.2	42,207	22.7
営業外収益	Non-Operating Income	576	0.6	487	0.5	1,187	0.9	1,828	1.2	762	0.4
受取利息及び配当金	Interest and Dividend Income	153	0.2	134	0.1	172	0.1	219	0.1	280	0.2
投資不動産収入	Income from Investment Real Estate	211	-	-	-	-	-	-	-	-	-
助成金	Subsidize revenue	-	-	171	0.2	128	0.1	-	-	310	0.2
為替差益	Foreign Exchange Gain	-	-	91	0.1	755	0.6	1,112	0.7	-	-
その他	Others	210	-	90	0.1	130	0.1	495	0.3	171	0.1
営業外費用	Non-Operating Expenses	1,004	1.0	111	0.1	151	0.1	207	0.1	1,898	1.0
支払利息及び割引料	Interest Expenses	76	-	46	-	23	-	27	0.0	19	0.0
売上割引	Sales Discounts	-	-	-	-	19	-	-	-	-	-
投資不動産維持費	Maintenance Cost of Investment Real Estate	49	-	-	-	-	-	-	-	-	-
為替差損	Foreign Exchange Loss	751	-	-	-	-	-	-	-	1,438	0.8
その他	Others	126	-	65	0.1	108	0.1	179	0.1	440	0.2
経常利益	Ordinary Income	13,226	13.6	15,568	15.4	23,159	17.8	33,137	21.3	41,071	22.1
特別利益	Extraordinary Profits	16	-	22	-	249	0.2	22	0.0	1,076	0.6
投資有価証券売却益	Gain on Sales of Investment Securities	-	-	-	-	-	-	-	-	-	-
固定資産売却益	Gains on Sale of Noncurrent Assets	12	-	11	-	6	-	22	0.0	18	0.0
その他	Others	3	-	10	-	242	0.2	-	-	1,057	0.6
特別損失	Extraordinary Loss	58	-	291	0.3	472	0.4	72	0.0	109	0.1
固定資産除売却損	Loss on Sales and Retirement of Noncurrent Assets	49	-	279	0.3	78	0.1	71	0.0	109	0.1
減損損失	Impairment Loss	-	-	-	-	231	0.2	-	-	-	-
投資有価証券等評価損	Loss on Valuation of Investment Securities	-	-	-	-	46	-	-	-	-	-
その他	Others	9	-	12	-	116	0.1	1	-	-	-
税金等調整前四半期純利益	Income before income taxes	13,183	13.6	15,299	15.1	22,936	17.7	33,087	21.2	42,037	22.6
法人税、住民税及び事業税	Income Taxes-current	4,780	4.9	5,212	5.1	9,195	7.1	10,996	7.1	12,876	6.9
法人税等調整額	Income Taxes-deferred	△194	△0.2	550	0.5	△261	△0.2	1,470	0.9	2,076	1.1
四半期純利益	Profit	8,597	8.9	9,535	9.4	14,002	10.8	20,620	13.2	27,085	14.6
非支配株主に帰属する四半期純利益	Profit Attributable to Non-Controlling Interests	13	-	17	-	△0	-	△0	-	△0	0.0
親会社株主に帰属する四半期純利益 ※2	Profit Attributable to Owners of Parent	8,584	8.9	9,518	9.4	14,002	10.8	20,620	13.2	27,085	14.6

※1 2015.3.1Qより、販売した製商品を顧客へ届けるための運送費を売上原価に計上する方法にグループ内で統一しました。なお、2014.3期については遡及適用後の財務諸表となっております。  
 ※During the first quarter of the fiscal year ending March 31, 2015, Sysmex has adopted consistently throughout the Group the practice of including transportation costs for shipping sold products to customers within cost of sales.  
 The financial statements for the fiscal year ended March 31, 2014, have been retroactively adjusted.

※2 2015年3月期以前の数値は「四半期(当期)純利益」の数値です。  
 ※2 Figures shown for fiscal years ended on or before March 31, 2015 are "Net income."

Consolidated Cash Flow Statement [3rd Quarter]

(百万円)  
(¥ million)

項目 Item		2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q
<b>営業活動によるキャッシュ・フロー</b>	<b>Net Cash Provided by (Used in) Operating Activities</b>					
税金等調整前四半期(当期)純利益	Income before income taxes	13,183	15,299	22,936	33,087	42,037
減価償却費	Depreciation and Amortization	5,260	5,775	7,178	8,357	9,133
減損損失	Impairment Loss	-	-	231	-	-
のれん償却額	Amortization of Goodwill	748	494	980	1,278	1,335
賞与引当金の増減額	Increase (Decrease) in Provision for Bonuses	△1,088	△1,471	△922	△950	△1,781
役員賞与引当金の増減額	Increase (Decrease) in Provision for Directors' Bonuses	△23	△69	△75	28	△23
退職給付引当金の増減額	Increase (Decrease) in Provision for Retirement Benefits	396	334	42	-	-
役員退職慰労引当金の増減額	Increase (Decrease) in Provision for Directors' Retirement Benefits	-	-	△57	-	-
貸倒引当金の増減額	Increase (Decrease) in Allowance for Doubtful Accounts	18	88	140	91	37
退職給付に係る負債の増減額	Increase (decrease) in net defined benefit liability	-	-	-	△326	△46
受取利息及び受取配当金	Interest and Dividend Income	△153	△134	△172	△219	△280
支払利息	Interest Expenses	76	46	23	27	19
持分法による投資損益	Equity in (Earnings) Losses of Affiliates	45	8	19	76	333
投資有価証券評価損	Loss (Gain) on valuation of Investment Securities	-	-	46	△0	-
固定資産除売却損	Loss on Retirement of Noncurrent Assets	36	267	72	70	91
売上債権の増減額	Decrease (Increase) in Notes and Accounts Receivable-trade	△1,426	3,617	5,386	455	1,182
たな卸資産の増減額	Increase (Decrease) in Inventories	△4,403	△3,985	△1,315	△6,723	△8,453
仕入債務の増減額	Increase (Decrease) in Notes and Accounts Payable-trade	834	1,205	△3,112	3,758	4,740
未払(未収)消費税等の増減額	Increase (Decrease) in Consumption Taxes Payable (Receivable)	111	109	12	△966	△212
その他	Others	1,881	952	△1,008	△265	△5,863
<b>小計</b>	<b>Total</b>	<b>15,499</b>	<b>22,538</b>	<b>30,404</b>	<b>37,759</b>	<b>42,250</b>
利息及び配当金の受取額	Interest and Dividends Received	139	133	173	209	282
利息の支払額	Interest Expenses Paid	△39	△32	△9	△16	△9
法人税等の支払額	Income Taxes Paid	△5,644	△5,975	△8,540	△13,840	△18,617
<b>営業活動によるキャッシュ・フロー</b>	<b>Net Cash Provided by (Used in) Operating Activities</b>	<b>9,955</b>	<b>16,664</b>	<b>22,270</b>	<b>24,111</b>	<b>23,905</b>



(百万円)  
(¥ million)

項目 Item	決算期 Fiscal Term	2012.3 3Q	2013.3 3Q	2014.3 3Q	2015.3 3Q	2016.3 3Q
<b>投資活動によるキャッシュ・フロー</b>	<b>Net Cash Provided by (Used in) Investment Activities</b>					
定期預金の預入による支出	Payments into Time Deposits	△24	△13	△134	△73	△123
定期預金の払い戻しによる収入	Proceeds from Withdrawal of Time Deposits	23	18	23	8	96
有形固定資産の取得による支出	Purchase of Property, Plant and Equipment	△4,777	△8,165	△9,109	△9,897	△10,364
有形固定資産の売却による収入	Proceeds from Sales of Property, Plan and Equipment	33	75	11	51	83
無形固定資産の取得による支出	Purchase of Intangible Assets	△1,172	△1,422	△2,652	△2,323	△3,993
投資有価証券の取得による支出	Purchase of Investment Securities	△370	-	△42	△2,249	△633
子会社株式の取得による収支	Purchase of Investments in Subsidiaries	-	-	△16,640	△68	-
事業譲受による支出	Payments for transfer of business	△1,900	-	-	-	-
その他	Others	△64	62	△225	△409	△247
<b>投資活動によるキャッシュ・フロー</b>	<b>Net Cash Provided by (Used in) Investment Activities</b>	<b>△7,754</b>	<b>△9,445</b>	<b>△28,768</b>	<b>△14,963</b>	<b>△15,181</b>
<b>財務活動によるキャッシュ・フロー</b>	<b>Net Cash Provided by (Used in) Financing Activities</b>					
短期借入金純増減額	Net Increase (Decrease) in Short-term Loans Payable	807	-	3,984	△1,000	-
長期借入金の返済による支出	Repayments of Long-term Loans Payable	△4	△4	△3	△148	△0
株式の発行による収入	Proceeds from Issuance of Common Stock	157	469	704	267	686
自己株式の取得による支出	Purchase of Treasury Stock	△3	△1	△8	△9	△4
配当金の支払額	Cash Dividends Paid	△3,184	△3,703	△4,544	△6,734	△9,549
その他	Others	△474	△225	△50	△53	△40
<b>財務活動によるキャッシュ・フロー</b>	<b>Net Cash Provided by (Used in) Financing Activities</b>	<b>△2,701</b>	<b>△3,464</b>	<b>81</b>	<b>△7,677</b>	<b>△8,908</b>
現金及び現金同等物に係る換算差額	Effect of Exchange Rate Change on Cash and Cash Equivalents	△623	843	2,820	3,493	△837
現金及び現金同等物の増減額	Net Increase (Decrease) in Cash and Cash Equivalents	△1,124	4,597	△3,595	4,964	△1,021
現金及び現金同等物の期首残高	Cash and Cash Equivalents at Beginning of Term	18,915	21,838	34,306	36,547	50,219
現金及び現金同等物の期首残高調整額	Increase (Decrease) of Cash and Cash Equivalents Due to Fiscal Year-end Change for Subsidiaries	-	-	-	-	△605
現金及び現金同等物の期末残高	Cash and Cash Equivalents at End of Term	17,791	26,435	30,711	41,511	48,592

Net Sales by Destination, Business and Product type [3rd Quarter]

地域別売上高

Net Sales by Destination

(百万円)  
(¥ million)

地域 Destination	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q			2016.3 通期予想 (Forecast)
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY <sup>※</sup> (%)		
国内	Japan	27,249	28.1	102.2	27,442	27.1	100.7	27,896	21.5	101.7	28,389	18.2	101.8	28,444	15.3	100.2	41,000
米州	Americas	20,925	21.6	108.8	21,050	20.8	100.6	28,166	21.7	133.8	33,933	21.8	120.5	43,576	23.5	128.4	58,000
EMEA	EMEA	27,694	28.6	107.5	27,743	27.4	100.2	37,862	29.2	136.5	47,194	30.3	124.6	51,573	27.8	109.3	68,900
中国	China	14,376	14.8	126.5	17,991	17.7	125.1	26,063	20.1	144.9	34,636	22.2	132.9	48,517	26.1	140.1	64,800
アジア・パシフィック	Asia-Pacific	6,666	6.9	99.7	7,154	7.1	107.3	9,859	7.6	137.8	11,698	7.5	118.7	13,573	7.3	116.0	19,300
海外計	Overseas Total	69,663	71.9	110.5	73,940	72.9	106.1	101,953	78.5	137.9	127,463	81.8	125.0	157,241	84.7	123.4	211,000
合計	Total Sales	96,913	100.0	108.0	101,383	100.0	104.6	129,849	100.0	128.1	155,852	100.0	120.0	185,685	100.0	119.1	252,000

●EMEA: 欧州、中東、アフリカ地域  
●EMEA: Europe, the Middle East and Africa

事業別売上高

Net Sales by Business

(百万円)  
(¥ million)

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q			2016.3 通期予想 (Forecast)
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY <sup>※</sup> (%)		
血球計数検査	Hematology	62,364	64.4	108.0	65,962	65.1	105.8	85,046	65.5	128.9	100,536	64.5	118.2	119,562	64.4	118.9	159,850
尿検査	Urinalysis	7,805	8.1	114.1	7,975	7.9	102.2	10,358	8.0	129.9	11,821	7.6	114.1	13,595	7.3	115.0	18,440
その他 ※1	Others ※1	-	-	-	-	-	-	-	-	-	982	0.6	-	1,297	0.7	132.1	1,410
HU-BU	HU-BU	70,169	72.4	108.6	73,938	72.9	105.4	95,405	73.5	129.0	113,340	72.7	118.8	134,454	72.4	118.6	179,700
免疫検査	Immunochemistry	1,467	1.5	74.4	1,425	1.4	97.1	1,581	1.2	111.0	2,297	1.5	145.2	4,094	2.2	178.2	7,500
生化学検査	Clinical Chemistry	2,381	2.5	104.5	1,946	1.9	81.8	2,506	1.9	128.7	2,773	1.8	110.7	2,699	1.5	97.3	3,920
血液凝固検査	Hemostasis	13,007	13.4	112.8	14,631	14.4	112.5	19,568	15.1	133.7	23,263	14.9	118.9	31,341	16.9	134.7	40,780
ICH-BU	ICH-BU	16,856	17.4	106.8	18,004	17.8	106.8	23,656	18.2	131.4	28,335	18.2	119.8	38,135	20.5	134.6	52,200
LS-BU	Life Science-BU	618	0.6	75.2	725	0.7	117.2	1,078	0.8	148.8	2,108	1.4	195.5	2,555	1.4	121.2	4,100
その他 ※2	Other Business ※2	9,267	9.6	109.0	8,715	8.6	94.0	9,708	7.5	111.4	12,068	7.7	124.3	10,538	5.7	87.3	16,000
合計	Total Sales	96,913	100.0	108.0	101,383	100.0	104.6	129,849	100.0	128.1	155,852	100.0	120.0	185,685	100.0	119.1	252,000

※1新興国向け簡易FCM製品等  
※1 Simple clinical FCM products for emerging markets, etc.  
※2 臨床検査情報システム(従来「HU-BUその他」に区分)、仕入商品(従来「その他IVD」に区分)、研究用・産業用FCM製品等  
※2 Clinical laboratory information systems (formerly included in "Others" in HU-BU), sales of third-party products (formerly included in "Other IVD"), FCM products for research and industry, etc.  
●前年同期実績数字は、2016年3月期から事業別売上区分を一部変更したことにより組み替えております。(「HU-BUその他」、「HU-BU」、「その他」)  
●Figures for the first three months of the fiscal year ended March 31, 2015, have been adjusted to align with changes in certain categories from the fiscal year ending March 31, 2016 ("Others" in HU-BU, "HU-BU" and "Others").

品目別売上高

Net Sales by Product Type

(百万円)  
(¥ million)

品目 Product Type	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q			2016.3 通期予想 (Forecast)
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY <sup>※</sup> (%)		
検体検査機器	Instrument	31,415	32.4	111.4	31,235	30.8	99.4	37,254	28.7	119.3	46,630	29.9	125.2	60,315	32.5	129.3	85,000
検体検査試薬	Reagent	44,387	45.8	108.3	47,917	47.3	108.0	63,897	49.2	133.3	76,420	49.0	119.6	86,054	46.3	112.6	114,700
保守サービス	Maintenance Service & Parts	9,484	9.8	105.9	9,965	9.8	105.1	13,043	10.0	130.9	15,882	10.2	121.8	18,550	10.0	116.8	24,000
その他	Others	11,626	12.0	100.5	12,265	12.1	105.5	15,653	12.1	127.6	16,919	10.9	108.1	20,764	11.2	122.7	28,300
合計	Total Sales	96,913	100.0	108.0	101,383	100.0	104.6	129,849	100.0	128.1	155,852	100.0	120.0	185,685	100.0	119.1	252,000

※前年同期を100%としています。  
※Previous period = 100%

●通期予想は、2015年11月に修正したものです。  
●Business forecast was revised in November 2015.

地域別・事業別売上高  
Net Sales by Destination and Business

連結データ  
Consolidated Data

(百万円)  
(¥ million)

■ 国内 Japan

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY <sup>※</sup> (%)	
血球計数検査 Hematology		11,740	43.1	106.6	12,402	45.2	105.6	12,020	43.1	96.9	12,191	42.9	101.4	12,580	44.2	103.2
尿検査 Urinalysis		1,554	5.7	108.9	1,425	5.2	91.7	1,557	5.6	109.3	1,490	5.2	95.7	1,623	5.7	108.9
その他 ※1 Others ※1		-	-	-	-	-	-	-	-	-	-	-	-	0	0.0	-
HU-BU HU-BU		13,294	48.8	106.9	13,828	50.4	104.0	13,577	48.7	98.2	13,681	48.2	100.8	14,204	49.9	103.8
免疫検査 Immunochemistry		1,452	5.3	74.6	1,408	5.1	97.0	1,564	5.6	111.0	1,927	6.8	123.2	2,495	8.8	129.5
生化学検査 Clinical Chemistry		1,372	5.0	108.2	1,317	4.8	96.0	1,491	5.3	113.2	1,161	4.1	77.9	1,054	3.7	90.8
血液凝固検査 Hemostasis		4,302	15.8	104.7	4,468	16.3	103.8	4,593	16.5	102.8	4,672	16.5	101.7	5,105	17.9	109.3
ICH-BU ICH-BU		7,127	26.2	97.3	7,194	26.2	100.9	7,648	27.4	106.3	7,761	27.3	101.5	8,655	30.4	111.5
LS-BU Life Science-BU		184	0.7	84.1	168	0.6	91.2	166	0.6	98.8	166	0.6	100.2	157	0.6	94.6
その他 ※2 Other Business ※2		6,641	24.4	99.3	6,251	22.8	94.1	6,503	23.3	104.0	6,778	23.9	104.2	5,426	19.1	80.1
合計 Total Sales		27,249	100.0	102.2	27,442	100.0	100.7	27,896	100.0	101.7	28,389	100.0	101.8	28,444	100.0	100.2

■ 海外 Overseas

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY <sup>※</sup> (%)	
血球計数検査 Hematology		50,623	72.7	108.3	53,559	72.4	105.8	73,026	71.6	136.3	88,345	69.3	121.0	106,982	68.0	121.1
尿検査 Urinalysis		6,251	9.0	115.4	6,549	8.9	104.8	8,801	8.6	134.4	10,331	8.1	117.4	11,971	7.6	115.9
その他 ※1 Others ※1		-	-	-	-	-	-	-	-	-	982	0.8	-	1,297	0.8	132.1
HU-BU HU-BU		56,874	81.6	109.0	60,109	81.3	105.7	81,827	80.3	136.1	99,658	78.2	121.8	120,250	76.5	120.7
免疫検査 Immunochemistry		15	0.0	57.9	16	0.0	110.6	17	0.0	105.6	370	0.3	2,100.7	1,599	1.0	432.2
生化学検査 Clinical Chemistry		1,008	1.4	99.9	629	0.9	62.4	1,014	1.0	161.2	1,612	1.3	158.9	1,644	1.0	102.0
血液凝固検査 Hemostasis		8,705	12.5	117.3	10,163	13.7	116.8	14,975	14.7	147.3	18,591	14.6	124.1	26,235	16.7	141.1
ICH-BU ICH-BU		9,729	14.0	115.0	10,809	14.6	111.1	16,007	15.7	148.1	20,573	16.1	128.5	29,479	18.7	143.3
LS-BU Life Science-BU		434	0.6	72.0	556	0.8	128.2	912	0.9	163.9	1,941	1.5	212.8	2,398	1.5	123.5
その他 ※2 Other Business ※2		2,626	3.8	144.4	2,463	3.3	93.8	3,205	3.1	130.1	5,289	4.1	165.0	5,112	3.3	96.7
合計 Total Sales		69,663	100.0	110.5	73,940	100.0	106.1	101,953	100.0	137.9	127,463	100.0	125.0	157,241	100.0	123.4

※1新興国向け簡易FCM製品等

※1 Simple clinical FCM products for emerging markets, etc.

※2 臨床検査情報システム(従来「HU-BUその他」に区分)、仕入商品(従来「その他IVD」に区分)、研究用・産業用FCM製品等

※2 Clinical laboratory information systems (formerly included in "Others" in HU-BU), sales of third-party products (formerly included in "Other IVD"), FCM products for research and industry, etc.

●前年同期実績数字は、2016年3月期から事業別売上区分を一部変更したことにより組み替えております。(「HU-BUその他」、「HU-BU」、「その他」)

●Figures for the first three months of the fiscal year ended March 31, 2015, have been adjusted to align with changes in certain categories from the fiscal year ending March 31, 2016 ("Others" in HU-BU, "HU-BU" and "Others").

※前年同期を100%としています。

※Previous period = 100%

(百万円)  
(¥ million)

■ 米州 Americas

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY*	
血球計数検査 Hematology		18,341	87.6	111.6	18,569	88.2	101.2	24,906	88.4	134.1	30,552	90.0	122.7	38,879	89.2	127.3
尿検査 Urinalysis		1,499	7.2	108.5	1,364	6.5	91.0	1,575	5.6	115.4	1,351	4.0	85.8	1,870	4.3	138.4
その他 ※1 Others ※1		-	-	-	-	-	-	-	-	-	42	0.1	-	129	0.3	307.1
HU-BU HU-BU		19,840	94.8	111.4	19,934	94.7	100.5	26,481	94.0	132.8	31,946	94.1	120.6	40,880	93.8	128.0
免疫検査 Immunochemistry		-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	-
生化学検査 Clinical Chemistry		-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	-
血液凝固検査 Hemostasis		1,046	5.0	76.4	1,079	5.1	103.1	1,590	5.6	147.3	1,813	5.3	114.0	2,146	4.9	118.4
ICH-BU ICH-BU		1,046	5.0	76.4	1,079	5.1	103.1	1,590	5.6	147.3	1,813	5.3	114.0	2,146	4.9	118.4
LS-BU Life Science-BU		-	-	-	-	-	-	-	-	-	0	0.0	-	453	1.0	-
その他 ※2 Other Business ※2		38	0.2	81.7	36	0.2	96.4	95	0.3	258.2	173	0.5	182.7	95	0.2	54.9
合計 Total Sales		20,925	100.0	108.8	21,050	100.0	100.6	28,166	100.0	133.8	33,933	100.0	120.5	43,576	100.0	128.4

■ EMEA

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY*	
血球計数検査 Hematology		20,049	72.4	105.6	20,106	72.5	100.3	27,665	73.1	137.6	32,380	68.6	117.0	35,883	69.6	110.8
尿検査 Urinalysis		1,747	6.3	104.4	1,668	6.0	95.4	2,266	6.0	135.9	2,507	5.3	110.6	2,523	4.9	100.6
その他 ※1 Others ※1		-	-	-	-	-	-	-	-	-	927	2.0	-	998	1.9	107.7
HU-BU HU-BU		21,796	78.7	105.5	21,774	78.5	99.9	29,931	79.1	137.5	35,815	75.9	119.7	39,405	76.4	110.0
免疫検査 Immunochemistry		6	0.0	53.7	11	0.0	183.4	10	0.0	92.3	6	0.0	63.3	4	0.0	66.7
生化学検査 Clinical Chemistry		199	0.7	43.3	110	0.4	55.6	162	0.4	146.7	232	0.5	143.0	177	0.3	76.3
血液凝固検査 Hemostasis		3,111	11.2	117.4	3,306	11.9	106.3	4,256	11.2	128.7	4,925	10.4	115.7	5,636	10.9	114.4
ICH-BU ICH-BU		3,316	12.0	106.2	3,429	12.4	103.4	4,430	11.7	129.2	5,164	10.9	116.6	5,819	11.3	112.7
LS-BU Life Science-BU		434	1.6	72.1	556	2.0	128.2	886	2.3	159.3	1,939	4.1	218.7	1,940	3.8	100.1
その他 ※2 Other Business ※2		2,146	7.8	154.7	1,982	7.1	92.4	2,614	6.9	131.9	4,275	9.1	163.5	4,408	8.5	103.1
合計 Total Sales		27,694	100.0	107.5	27,743	100.0	100.2	37,862	100.0	136.5	47,194	100.0	124.6	51,573	100.0	109.3

● EMEA: 欧州、中東、アフリカ地域  
● EMEA: Europe, the Middle East and Africa

※1 新興国向け簡易FCM製品等

※1 Simple clinical FCM products for emerging markets, etc.

※2 臨床検査情報システム(従来「HU-BUその他」に区分)、仕入商品(従来「その他IVD」に区分)、研究用・産業用FCM製品等

※2 Clinical laboratory information systems (formerly included in "Others" in HU-BU), sales of third-party products (formerly included in "Other IVD"), FCM products for research and industry, etc.

● 前年同期実績数字は、2016年3月期から事業別売上区分を一部変更したことにより組み替えております。(「HU-BUその他」、「HU-BU」、「その他」)

● Figures for the first three months of the fiscal year ended March 31, 2015, have been adjusted to align with changes in certain categories from the fiscal year ending March 31, 2016 ("Others" in HU-BU, "HU-BU" and "Others")

※前年同期を100%としています。

※Previous period = 100%

(百万円)  
(\* million)

■ 中国 China

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY** (%)	
血球計数検査 Hematology		7,316	50.9	115.9	9,708	54.0	132.7	13,506	51.8	139.1	17,591	50.8	130.2	23,055	47.5	131.1
尿検査 Urinalysis		2,656	18.5	133.4	3,089	17.2	116.3	4,158	16.0	134.6	5,438	15.7	130.8	6,384	13.2	117.4
その他 ※1 Others ※1		-	-	-	-	-	-	-	-	-	-	-	-	2	0.0	-
HU-BU HU-BU		9,972	69.4	120.1	12,797	71.1	128.3	17,664	67.8	138.0	23,030	66.5	130.4	29,442	60.7	127.8
免疫検査 Immunochemistry		2	0.0	106.7	3	0.0	167.9	4	0.0	110.3	345	1.0	8,342.5	1,567	3.2	454.2
生化学検査 Clinical Chemistry		737	5.1	155.1	460	2.6	62.5	748	2.9	162.5	1,059	3.1	141.6	933	1.9	88.1
血液凝固検査 Hemostasis		3,516	24.5	143.6	4,573	25.4	130.1	7,537	28.9	164.8	10,198	29.4	135.3	16,549	34.1	162.3
ICH-BU ICH-BU		4,256	29.6	145.4	5,038	28.0	118.4	8,290	31.8	164.5	11,604	33.5	140.0	19,050	39.3	164.2
LS-BU Life Science-BU		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
その他 ※2 Other Business ※2		147	1.0	110.6	155	0.9	105.6	108	0.4	69.5	2	0.0	2.2	24	0.1	1,200.0
合計 Total Sales		14,376	100.0	126.5	17,991	100.0	125.1	26,063	100.0	144.9	34,636	100.0	132.9	48,517	100.0	140.1

■ アジア・パシフィック Asia-Pacific

事業 Business	決算期 Fiscal Term	2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY (%)		Ratio (%)	YOY** (%)	
血球計数検査 Hematology		4,916	73.7	97.9	5,175	72.3	105.3	6,948	70.5	134.3	7,820	66.9	112.6	9,163	67.5	117.2
尿検査 Urinalysis		347	5.2	94.1	427	6.0	123.0	801	8.1	187.3	1,033	8.8	129.0	1,192	8.8	115.4
その他 ※1 Others ※1		-	-	-	-	-	-	-	-	-	11	0.1	-	167	1.2	1,518.2
HU-BU HU-BU		5,263	79.0	97.6	5,602	78.3	106.4	7,749	78.6	138.3	8,866	75.8	114.4	10,523	77.5	118.7
免疫検査 Immunochemistry		6	0.1	53.7	1	0.0	21.7	2	0.0	200.3	17	0.2	614.6	26	0.2	152.9
生化学検査 Clinical Chemistry		72	1.1	96.8	58	0.8	80.6	103	1.0	178.0	319	2.7	309.3	533	3.9	167.1
血液凝固検査 Hemostasis		1,030	15.5	108.2	1,203	16.8	116.7	1,590	16.1	132.2	1,654	14.1	104.0	1,903	14.0	115.1
ICH-BU ICH-BU		1,109	16.6	106.7	1,262	17.7	113.8	1,696	17.2	134.4	1,991	17.0	117.4	2,463	18.1	123.7
LS-BU Life Science-BU		-	-	-	-	-	-	25	0.3	-	2	0.0	8.9	4	0.0	200.0
その他 ※2 Other Business ※2		293	4.4	116.8	288	4.0	98.2	387	3.9	134.4	838	7.2	216.4	583	4.3	69.6
合計 Total Sales		6,666	100.0	99.7	7,154	100.0	107.3	9,859	100.0	137.8	11,698	100.0	118.7	13,573	100.0	116.0

※1新興国向け簡易FCM製品等

※1 Simple clinical FCM products for emerging markets, etc.

※2 臨床検査情報システム(従来「HU-BUその他」に区分)、仕入商品(従来「その他IVD」に区分)、研究用・産業用FCM製品等

※2 Clinical laboratory information systems (formerly included in "Others" in HU-BU), sales of third-party products (formerly included in "Other IVD"), FCM products for research and industry, etc.

●前年同期実績数字は、2016年3月期から事業別売上区分を一部変更したことにより組み替えております。(「HU-BUその他」、「HU-BU」、「その他」)

●Figures for the first three months of the fiscal year ended March 31, 2015, have been adjusted to align with changes in certain categories from the fiscal year ending March 31, 2016 ("Others" in HU-BU, "HU-BU" and "Others").

※前年同期を100%としています。

※Previous period = 100%

地域別・品目別売上高  
Net Sales by Destination and Product type

(百万円)  
(\$ million)

決算期 Fiscal Term			2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q		
			Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)			
地域 Destination			Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)			
日本 Japan	検体検査機器	Instrument	7,775	28.5	106.3	7,575	27.6	97.4	7,504	26.9	99.1	7,163	25.2	95.5	5,515	19.4	77.0
	検体検査試薬	Reagent	14,763	54.2	104.0	15,096	55.0	102.3	15,285	54.8	101.3	16,168	57.0	105.8	17,504	61.5	108.3
	保守サービス	Maintenance Service & Parts	2,525	9.3	102.7	2,632	9.6	104.2	2,865	10.3	108.9	3,032	10.7	105.8	3,255	11.4	107.4
	その他	Others	2,185	8.0	81.2	2,138	7.8	97.8	2,241	8.0	104.8	2,025	7.1	90.4	2,167	7.6	107.0
	合計	Total Sales	27,249	100.0	102.2	27,442	100.0	100.7	27,896	100.0	101.7	28,389	100.0	101.8	28,444	100.0	100.2
米州 Americas	検体検査機器	Instrument	7,044	33.7	121.9	5,738	27.3	81.5	7,314	26.0	127.5	9,602	28.3	131.3	13,406	30.8	139.6
	検体検査試薬	Reagent	6,605	31.6	102.4	7,437	35.3	112.6	10,138	36.0	136.3	12,007	35.4	118.4	14,720	33.8	122.6
	保守サービス	Maintenance Service & Parts	3,880	18.5	108.9	4,413	21.0	113.7	6,148	21.8	139.3	7,303	21.5	118.8	9,327	21.4	127.7
	その他	Others	3,395	16.2	98.7	3,462	16.4	102.0	4,566	16.2	131.9	5,020	14.8	109.9	6,121	14.0	121.9
	合計	Total Sales	20,925	100.0	108.8	21,050	100.0	100.6	28,166	100.0	133.8	33,933	100.0	120.5	43,576	100.0	128.4
EMEA	検体検査機器	Instrument	6,860	24.8	103.2	6,645	24.0	96.9	8,568	22.6	128.9	11,863	25.1	138.5	14,817	28.7	124.9
	検体検査試薬	Reagent	12,672	45.8	107.1	12,973	46.8	102.4	18,582	49.1	143.2	22,469	47.6	120.9	24,173	46.9	107.6
	保守サービス	Maintenance Service & Parts	2,705	9.8	107.0	2,497	9.0	92.3	3,474	9.2	139.1	4,820	10.2	138.7	5,113	9.9	106.1
	その他	Others	5,455	19.7	114.7	5,625	20.3	103.1	7,237	19.1	128.7	8,040	17.0	111.1	7,468	14.5	92.9
	合計	Total Sales	27,694	100.0	107.5	27,743	100.0	100.2	37,862	100.0	136.5	47,194	100.0	124.6	51,573	100.0	109.3
中国 China	検体検査機器	Instrument	7,194	50.0	120.9	9,009	50.1	125.2	11,498	44.1	127.6	15,174	43.8	132.0	23,426	48.3	154.4
	検体検査試薬	Reagent	7,035	48.9	134.7	8,797	48.9	125.0	14,326	55.0	162.9	19,186	55.4	133.9	24,694	50.9	128.7
	保守サービス	Maintenance Service & Parts	121	0.8	73.3	148	0.8	122.3	207	0.8	139.9	239	0.7	115.5	308	0.6	128.9
	その他	Others	24	0.2	114.3	35	0.2	145.8	30	0.1	85.7	36	0.1	120.0	87	0.2	241.7
	合計	Total Sales	14,376	100.0	126.5	17,991	100.0	125.1	26,063	100.0	144.9	34,636	100.0	132.9	48,517	100.0	140.1
アジア・ パシフィック Asia- Pacific	検体検査機器	Instrument	2,540	38.1	101.0	2,266	31.7	89.2	2,368	24.0	104.5	2,827	24.2	119.4	3,149	23.2	111.4
	検体検査試薬	Reagent	3,310	49.7	101.2	3,612	50.5	109.1	5,565	56.4	154.1	6,587	56.3	118.4	4,961	36.6	75.3
	保守サービス	Maintenance Service & Parts	251	3.8	104.1	272	3.8	108.4	348	3.5	127.9	486	4.2	139.7	543	4.0	111.7
	その他	Others	564	8.5	86.0	1,003	14.0	177.8	1,577	16.0	157.2	1,797	15.4	114.0	4,919	36.2	273.7
	合計	Total Sales	6,666	100.0	99.7	7,154	100.0	107.3	9,859	100.0	137.8	11,698	100.0	118.7	13,573	100.0	116.0
計 Total	検体検査機器	Instrument	31,415	32.4	111.4	31,235	30.8	99.4	37,254	28.7	119.3	46,630	29.9	125.2	60,315	32.5	129.3
	検体検査試薬	Reagent	44,387	45.8	108.3	47,917	47.3	108.0	63,897	49.2	133.3	76,420	49.0	119.6	86,054	46.3	112.6
	保守サービス	Maintenance Service & Parts	9,484	9.8	105.9	9,965	9.8	105.1	13,043	10.0	130.9	15,882	10.2	121.8	18,550	10.0	116.8
	その他	Others	11,626	12.0	100.5	12,265	12.1	105.5	15,653	12.1	127.6	16,919	10.9	108.1	20,764	11.2	122.7
	合計	Total Sales	96,913	100.0	108.0	101,383	100.0	104.6	129,849	100.0	128.1	155,852	100.0	120.0	185,685	100.0	119.1

●EMEA: 欧州、中東、アフリカ地域  
●EMEA: Europe, the Middle East and Africa

※前年同期を100%としています。  
※Previous period = 100%

所在地別売上高および営業利益の状況 [第3四半期累計]

連結データ  
Consolidated Data

Net Sales and Operating Income (Loss) by Geographical Region  
(Net Sales and Operating Income (Loss) of Subsidiaries in the Region) [3rd Quarter]

決算期 Fiscal Term			2012.3 3Q			2013.3 3Q			2014.3 3Q			2015.3 3Q			2016.3 3Q			2016.3 通期予想 (Forecast)
			Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)	Ratio (%)	YOY (%)				
所在地 Geographical Region																		
日本 Japan	外部売上高 Sales to Customers	30,029	50.2	102.9	29,449	47.6	98.1	28,724	39.2	97.5	30,139	35.9	104.9	30,993	30.3	102.8	44,100	
	内部売上高 Intra-area Transfer	29,743	49.8	115.3	32,437	52.4	109.1	44,485	60.8	137.1	53,846	64.1	121.0	71,209	69.7	132.2	99,000	
	売上高計 Total Sales	59,772	100.0	108.7	61,887	100.0	103.5	73,209	100.0	118.3	83,986	100.0	114.7	102,203	100.0	121.7	143,100	
	営業費用 Operating Expenses	53,366	89.3	107.5	54,096	87.4	101.4	59,671	81.5	110.3	64,000	76.2	107.3	70,893	69.4	110.8	104,500	
	営業利益 Operating Income	6,406	10.7	120.5	7,790	12.6	121.6	13,537	18.5	173.8	19,985	23.8	147.6	31,310	30.6	156.7	38,600	
米州 Americas	外部売上高 Sales to Customers	19,736	100.0	107.5	20,405	100.0	103.4	27,349	100.0	134.0	32,429	99.7	118.6	40,941	98.3	126.2	55,700	
	内部売上高 Intra-area Transfer	1	-	100.0	1	-	100.0	4	-	400.0	104	0.3	2,600.0	690	1.7	663.5	1,000	
	売上高計 Total Sales	19,738	100.0	107.5	20,407	100.0	103.4	27,353	100.0	134.0	32,533	100.0	118.9	41,631	100.0	128.0	56,700	
	営業費用 Operating Expenses	17,478	88.5	108.1	19,036	93.3	108.9	25,733	94.1	135.2	30,739	94.5	119.5	40,034	96.2	130.2	54,100	
	営業利益 Operating Income	2,260	11.5	102.8	1,370	6.7	60.6	1,620	5.9	118.2	1,794	5.5	110.7	1,597	3.8	89.0	2,600	
EMEA	外部売上高 Sales to Customers	27,519	98.8	107.1	27,592	98.8	100.3	37,793	98.7	137.0	46,911	98.3	124.1	51,723	98.0	110.3	68,400	
	内部売上高 Intra-area Transfer	338	1.2	172.4	341	1.2	100.9	497	1.3	145.7	828	1.7	166.6	1,064	2.0	128.5	1,500	
	売上高計 Total Sales	27,858	100.0	107.6	27,934	100.0	100.3	38,290	100.0	137.1	47,740	100.0	124.7	52,788	100.0	110.6	69,900	
	営業費用 Operating Expenses	23,960	86.0	107.3	23,741	85.0	99.1	31,776	83.0	133.8	43,522	91.2	137.0	50,685	96.0	116.5	67,100	
	営業利益 Operating Income	3,897	14.0	109.3	4,192	15.0	107.6	6,514	17.0	155.4	4,217	8.8	64.7	2,103	4.0	49.9	2,800	
中国 China	外部売上高 Sales to Customers	14,376	100.0	126.5	17,988	100.0	125.1	26,054	100.0	144.8	34,630	100.0	132.9	48,477	100.0	140.0	64,800	
	内部売上高 Intra-area Transfer	4	-	100.0	3	-	75.0	4	-	133.3	4	-	100.0	3	0.0	75.0	-	
	売上高計 Total Sales	14,380	100.0	126.5	17,992	100.0	125.1	26,059	100.0	144.8	34,634	100.0	132.9	48,481	100.0	140.0	64,800	
	営業費用 Operating Expenses	12,429	86.4	135.2	16,004	89.0	128.8	22,958	88.1	143.5	29,488	85.1	128.4	43,557	89.8	147.7	58,700	
	営業利益 Operating Income	1,950	13.6	89.6	1,987	11.0	101.9	3,101	11.9	156.1	5,146	14.9	165.9	4,924	10.2	95.7	6,100	
アジア・ パシフィック Asia- Pacific	外部売上高 Sales to Customers	5,250	98.2	103.1	5,947	98.0	113.3	9,927	98.8	166.9	11,742	99.0	118.3	13,548	99.9	115.4	19,000	
	内部売上高 Intra-area Transfer	94	1.8	70.1	118	2.0	125.5	118	1.2	100.0	117	1.0	99.2	19	0.1	16.2	200	
	売上高計 Total Sales	5,345	100.0	102.3	6,066	100.0	113.5	10,045	100.0	165.6	11,859	100.0	118.1	13,567	100.0	114.4	19,200	
	営業費用 Operating Expenses	5,213	97.5	112.7	5,490	90.5	105.3	8,796	87.6	160.2	10,843	91.4	123.3	12,211	90.0	112.6	17,900	
	営業利益 Operating Income	131	2.5	21.8	575	9.5	438.9	1,249	12.4	217.2	1,015	8.6	81.3	1,356	10.0	133.6	1,300	
計 Total	外部売上高 Sales to Customers	96,913	76.3	108.0	101,383	75.5	104.6	129,849	74.2	128.1	155,852	74.0	120.0	185,685	71.8	119.1	252,000	
	内部売上高 Intra-area Transfer	30,182	23.7	115.5	32,904	24.5	109.0	45,110	25.8	137.1	54,901	26.0	121.7	72,987	28.2	132.9	101,700	
	売上高計 Total Sales	127,095	100.0	109.7	134,287	100.0	105.7	174,959	100.0	130.3	210,754	100.0	120.5	258,672	100.0	122.7	353,700	
	営業費用 Operating Expenses	112,448	88.5	110.3	118,370	88.1	105.3	148,936	85.1	125.8	178,594	84.7	119.9	217,381	84.0	121.7	302,300	
	営業利益 Operating Income	14,646	11.5	105.7	15,917	11.9	108.7	26,023	14.9	163.5	32,159	15.3	123.6	41,290	16.0	128.4	51,400	
消去/ 全社 Eliminations/ Corporate	外部売上高 Sales to Customers	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	内部売上高 Intra-area Transfer	△30,182	-	-	△32,904	-	-	△45,110	-	-	△54,901	-	-	△72,987	-	-	△101,700	
	売上高計 Total Sales	△30,182	-	-	△32,904	-	-	△45,110	-	-	△54,901	-	-	△72,987	-	-	△101,700	
	営業費用 Operating Expenses	△29,190	-	-	△32,179	-	-	△41,211	-	-	△54,258	-	-	△73,903	-	-	△102,300	
	営業利益 Operating Income	△992	-	-	△724	-	-	△3,899	-	-	△642	-	-	916	-	-	600	
連結 Consolidated	外部売上高 Sales to Customers	96,913	100.0	108.0	101,383	100.0	104.6	129,849	100.0	128.1	155,852	100.0	120.0	185,685	100.0	119.1	252,000	
	内部売上高 Intra-area Transfer	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
	売上高計 Total Sales	96,913	100.0	108.0	101,383	100.0	104.6	129,849	100.0	128.1	155,852	100.0	120.0	185,685	100.0	119.1	252,000	
	営業費用 Operating Expenses	83,258	85.9	109.2	86,190	85.0	103.5	107,725	83.0	125.0	124,335	79.8	115.4	143,478	77.3	115.4	200,000	
	営業利益 Operating Income	13,654	14.1	101.5	15,192	15.0	111.3	22,123	17.0	145.6	31,517	20.2	142.5	42,207	22.7	133.9	52,000	

- 日本所在地には、モンゴル、アイデックス社向けなどの売上、利益を含みます。
- Sales and Operating Income in Japan include those to Mongolia, IDEXX and other countries.
- EMEA: 欧州、中東、アフリカ地域
- EMEA: Europe, the Middle East and Africa
- アジア・パシフィック所在地には、モンゴルの売上、利益を含みません。
- Sales in Asia Pacific exclude Mongolia.

※前年同期を100%としています。  
※Previous period = 100%


●通期予想は、2015年11月に修正したものです。  
●Business forecast was revised in November 2015.



株式情報

Stock Information


シスメックス株式会社の株価推移と出来高  
Stock Price Range and Trading Volume of Sysmex Corporation




※1: 2011年4月1日付で1株を2株に株式分割を実施しました。  
※1: The shares of shareholders was split two for one on April 1, 2011.

※2: 2014年4月1日付で1株を2株に株式分割を行っております。  
そのため、前連結会計年度の期首に当該分割が行われたと仮定して期末発行済株式数を算定しております。  
※2: The Company conducted a two-for-one stock split on April 1, 2014.  
Accordingly, calculations involving the number of shares issued as of the end of the fiscal year are performed as if the stock split had been conducted at the beginning of the previous fiscal year.


株式の所有者別状況 ※3  
Composition of Shareholders by Category



株主数の推移  
Number of Shareholders



発行済株式数の推移  
Number of Shares Issued (千株)  
(thousand shares)





## 会社概要

### Corporate Data

#### シスメックス株式会社

Sysmex Corporation

本社所在地  
Address of Head Office 〒651-0073 兵庫県神戸市中央区脇浜海岸通1丁目5番1号  
1-5-1, Wakinohama-Kaigandori, Chuo-ku, Kobe, Hyogo 651-0073, Japan

電話番号 Telephone (078) 265-0500 (代表)  
F A X Facsimile (078) 265-0524

設立年月日  
Date of Establishment 昭和43年2月20日  
February 20, 1968

資本金  
Paid-in Capital 10,912,186 (千円)  
¥ thousand

従業員数  
Number of Employees 2,520名(単独/Non-Consolidated)  
7,407名(連結/Consolidated)  
※嘱託及びパートタイマーなどを含む  
※Including part-time employee  
従業員平均年齢 average age 40.2才  
従業員平均勤続年数 average years of employment 11.4年

発行済株式総数  
Number of Shares Issued 208,279 千株 ※  
(thousand shares)

決算期  
Settlement Day 3月31日  
March 31

上場市場  
Stock Listings 東京証券取引所市場第一部  
Tokyo Stock Exchange, First Section

証券コードNo.  
Stock Exchange Code Number 6869

※: 2014年4月1日付で1株を2株に株式分割を行っております。  
そのため、前連結会計年度の期首に当該分割が行われたと仮定して期末発行済株式数を算定しております。

※: The Company conducted a two-for-one stock split on April 1, 2014.

Accordingly, calculations involving the number of shares issued as of the end of the fiscal year are performed as if the stock split had been conducted at the beginning of the previous fiscal year.

主な事業内容  
Main Line of Business

臨床検査機器、検査用試薬ならびに関連ソフトウェアなどの  
開発・製造・販売・輸出入  
Development, manufacture, sales, import and export of diagnostics  
instruments and reagents, and related software


主な販売先  
Customers

国立病院、一般病院、大学、研究所、その他医療機関  
National and public hospitals, general hospitals,  
and other medical institutions, universities, and research institutes

事業所  
Offices

本社 Head Office	仙台支店 Sendai Branch	千葉営業所 Chiba Sales Office
テクノパーク Technopark	北関東支店 Kita Kanto Branch	横浜営業所 Yokohama Sales Office
ソリューションセンター Solution Center	東京支店 Tokyo Branch	静岡営業所 Shizuoka Sales Office
研究開発センター R&D Center	名古屋支店 Nagoya Branch	金沢営業所 Kanazawa Sales Office
アイスクエア i-Square	大阪支店 Osaka Branch	京都営業所 Kyoto Sales Office
加古川工場 Kakogawa Factory	広島支店 Hiroshima Branch	神戸営業所 Kobe Sales Office
タンパク質開発センター Protein Development Center	福岡支店 Fukuoka Branch	高松営業所 Takamatsu Sales Office
東京支社 Tokyo Office	札幌営業所 Sapporo Sales Office	岡山営業所 Okayama Sales Office
	盛岡営業所 Morioka Sales Office	鹿児島営業所 Kagoshima Sales Office
	長野営業所 Nagano Sales Office	首都圏サービスセンター Metropolitan Area Service Center
	新潟営業所 Niigata Sales Office	

(2015年12月31日現在)  
(As of December 31, 2015)



**Sysmex Corporation**

1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan  
Tel. +81(78)265-0500 Fax. +81(78)265-0524

[www.sysmex.co.jp](http://www.sysmex.co.jp)

Printed in Japan